Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug.
about
Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic chargeThe science of nebulised drug delivery.Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.A non-electrostatic spacer for aerosol deliveryReducing electrostatic charge on spacer devices and bronchodilator response.Differences in aerodynamic particle size distributions of innovator and generic beclomethasone dipropionate aerosols used with and without a large volume spacerThe rejuvenated pressurised metered dose inhaler.The challenge of delivering therapeutic aerosols to asthma patientsElectrostatics of pharmaceutical inhalation aerosols.Inhalable nanocomposite microparticles: preparation, characterization and factors affecting formulation.Optimizing inhaled drug delivery in patients with asthma.Inhalational drug delivery from seven different spacer devices.Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.Particle size selection device for use with the TurbohalerDelivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation?A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and Aerochamber spacer devices.Delivery of inhaled medication to children.The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.Optimum use of a spacer device.Emergency treatment of asthma.Asthma drug delivery devices for childrenTargeting drug delivery to the lungs by inhalation.Delivery of salbutamol pressurized metered-dose inhaler administered via small-volume spacer devices in intubated, spontaneously breathing rabbits.Relative lung and systemic bioavailability of sodium cromoglycate inhaled products using urinary drug excretion post inhalation.Spirometry with bronchodilator test: effect that the use of large-volume spacers with antistatic treatment has on test response.Spacer devices for inhaled therapy: why use them, and how?
P2860
Q28346185-1D33E5FD-B2F4-4B4A-8F81-8D786F5C1556Q30496400-1B4B3E11-1838-4676-8A5C-BE566A7419DBQ33976334-B9EC217D-7AAA-41CC-A092-54DBD566EB73Q34797065-A640B356-B5D6-4CA2-8E14-F53181F99523Q36055281-BD45F9F5-5FB9-4D50-9DFC-547021D5245DQ36567169-2695B8D1-8B7E-4F43-B3C3-72A2C6496F6AQ36815920-062AE6D7-33BB-4740-BFE0-90D84B932E37Q37105708-0D395685-B8D3-44D7-B97F-3A7AFF6099CAQ37643843-7092BCB8-88D4-4592-B3A1-0E19CDEC0A67Q38619134-ECF130E8-3CF5-4170-862F-0C945D5EAB72Q41068716-960293F5-081E-4CAF-A4C4-259BD14154C9Q41207183-2C3ADEC0-9BF9-42E4-9FED-3AD612F1E640Q41207768-870E598D-0B0F-4A73-BCD4-76BDD620DCB5Q41207776-4D80FE2E-C0FA-4D15-8049-5D67FF30C606Q41219041-63498D7E-F3FE-4A2F-BD30-A9D100D4C53AQ41234688-307128E0-7981-4A7E-B381-B0E288536E6FQ41593628-81F405A4-AE67-4FFA-AEB7-293C244BCAC6Q41680896-657A57EA-6E3A-4885-9FFE-242E25EE7659Q41851729-4B090362-075C-4FC5-B656-2B1A5A32FBC3Q42129640-003A8199-835A-4625-9A9B-6CE4677E191FQ42416600-CBCE0D33-F1F2-4435-BD63-9251B30DECBAQ42766553-A9F75049-FB7A-4647-BA65-13CB35EE520CQ43204099-F792D9D3-B769-4EF3-AA8D-067F6EE208BDQ43717152-FF888C1F-F58B-42EB-A6C3-67C8DE367D07Q43996962-30BCFC83-0B26-487C-89BC-56738F2B36D0Q50976159-3C48C726-F023-4969-A1B6-614EFCA0B202Q55241851-422C1FCB-7BF8-4B3C-A04D-A77CDE9B33F7
P2860
Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Improvement in sodium cromogly ...... g multiple actuations of drug.
@en
type
label
Improvement in sodium cromogly ...... g multiple actuations of drug.
@en
prefLabel
Improvement in sodium cromogly ...... g multiple actuations of drug.
@en
P2093
P356
P1433
P1476
Improvement in sodium cromogly ...... g multiple actuations of drug.
@en
P2093
P2860
P304
P356
10.1136/THX.48.6.603
P407
P577
1993-06-01T00:00:00Z